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Abstract
Cathepsin K (CTSK) is a member of the papain-like cysteine protease family. Mutations in the CTSK gene cause a
rare autosomal recessive bone disorder called pycnodysostosis (OMIM 265800). In order to follow the advances in
the research about CTSK and pycnodysostosis, we performed a literature retrospective study of 159
pycnodysostosis patients reported since 1996 and focused on the genetic characteristics of CTSK mutations and/or
the clinical phenotypes of pycnodysostosis. Thirty three different CTSK mutations have been found in 59 unrelated
pycnodysostosis families. Of the 59 families, 37.29% are from Europe and 30.51% are from Asia. A total of 69.70% of
the mutations were identified in the mature domain of CTSK, 24.24% in the proregion, and 6.06% in the preregion.
The hot mutation spots are found in exons 6 and 7. CTSK mutations result in total loss or inactivity of the CTSK
protein, which causes abnormal degradation of bone matrix proteins such as type I collagen. Skeletal abnormalities,
including short stature, an increase in bone density with pathologic fractures, and open fontanels and sutures, are
the typical phenotypes of pycnodysostosis. Research on Ctsk
-/- mouse models was also reviewed here to elucidate
the biological function of Ctsk and the mechanism of pycnodysostosis. New evidence suggests that Ctsk plays an
important role in the immune system and may serve as a valid therapeutic target in the future treatment of
pycnodysostosis.
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Introduction
Pycnodysostosis (OMIM 265800) is a rare autosomal
recessive bone disorder resulting from osteoclast dysfunc-
tion [1-4]. The first case of pycnodysostosis was described
in 1923 by Montanari; however, Maroteaux and Lamy
defined the typical features ofp y c n o d y s o s t o s i s( G r e e k :
pycnos = dense; dys = defective; osteon = bone) in 1962.
Thus, it is also known as Maroteaux-Lamy syndrome.
This disorder is also called Toulouse-Lautrec syndrome
after the famous French artist Henri de Toulouse-Lautrec,
who was thought to be afflicted with the disease [2,3,5].
Less than 200 cases have been reported worldwide since
1962 [1]. The prevalence of pycnodysostosis is estimated
to be 1 to 1.7 per million with equal sex distribution [4-7].
The typical features of pycnodysostosis include short sta-
ture, an increase in the bone density of long bones, patho-
logical fractures with poor healing, stubby hands and feet
with dystrophic nails, unossified fontanels, and an obtuse
mandibular angle [5,8-10].
The candidate gene for pycnodysostosis was mapped to
human chromosome 1q21 by genetic linkage analysis, and
was subsequently identified as coding for cathepsin K
(CTSK, MIM# 601105) by a positional cloning strategy in
1996 [11-13]. The CTSK gene spans approximately 12 kb
(GenBank acc. no., NC_000001.10) and contains 8 exons
(GenBank acc. no., NM_000396.2). The codon for the
translation initiator methionine (Met1) is located in exon
2, whereas the termination codon is located in exon 8. The
CTSK protein, highly similar to cathepsins S and L, is a
member of the papain-like cysteine protease family. Like
most papain-like cysteine proteases, CTSK consists of 329
amino acids (GenBank acc. no., NP_000387.1), including a
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any medium, provided the original work is properly cited.15-amino acid preregion, a 99-amino acid proregion, and a
215-amino acid mature active enzyme [14]. CTSK is
synthesized as an inactive precursor protein and requires
removal of its N-terminal proregion for activation. This
autocatalytic process occurs under a low-pH environment
[3].
To date, it is difficult to find a full description of the
characteristics of specific gene mutations and clinical
manifestations of pycnodysostosis in the literature. In
this study, we analyzed the reported CTSK mutations and
summarized the typical clinical features of pycnodysosto-
sis from 159 reported patients and some animal research
findings in Ctsk gene knockout mice (Ctsk
-/- mice). Early
reports of CTSK mutations were renamed in this study
with the first base in the CTSK gene (GenBank acc. no.,
NC_000001.10) as the +1 position in genomic DNA, and
the A of the ATG-translation initiation codon as nucleo-
tide +1 in cDNA (GenBank acc. no., NM_000396.2).
Structure of CTSK
CTSK is also called lysosomal cysteine cathepsin K
because it contains a cysteine in its active site and func-
tions mainly in lysosomes [15]. Like most lysosomal
cysteine proteases, CTSK is synthesized as an inactive
proenzyme [3,16]. The preregion plays a critical role in
targeting the protein to the endoplasmic reticulum and
translocating the protein across the membrane [17-19].
While the proregion plays a role in protein folding and
intracellular trafficking, it can also inhibit protease func-
tion until the proenzyme reaches the lysosome [20]. The
proregion contains a conserved N-glycosylation site
(Asn103), which is supposed to facilitate lysosomal traf-
ficking via the mannose 6-phosphate receptor pathway
[11,14,20]. The proenzyme requires removal of its N-term-
inal proregion for activation [16]. This process has been
proven to be autocatalytic in lysosomes at a pH of 4 [3,21].
CTSK consists of 2 domains folded together, resulting in a
V-shaped configuration [22,23]. The catalytic triad, con-
sisting of Cys139, His276, and Asn296 in the active sites,
localizes at the bottom of the V cleft [14,15,24,25].
Distribution of CTSK
CTSK is highly expressed in osteoclasts and has lower
expression levels in the heart, lung, skeletal muscle,
colon, ovary, and placenta [3,5,20]. Additionally, CTSK
mRNA was detected in macrophages and bone marrow-
derived dendritic cells, but was barely detected in non-
adherent bone marrow cells or splenic T cells [26,27].
Function of CTSK
In osteoclasts
CTSK, which is critical for osteoclast-mediated bone
resorption, is highly expressed in osteoclasts. In osteo-
clasts, CTSK is responsible for the degradation of bone
matrix proteins, such as type I collagen, osteopontin,
and osteonectin [3,5,20]. A tightly sealed resorption
lacuna between the osteoclast and the bone is called an
extracellular lysosome. Dissolution of the inorganic
matrix and degradation of the organic matrix occur in
the extracellular lysosome under low pH conditions
[28,29]. In mature osteoclasts, CTSK is synthesized as
an inactive proenzyme and cleaved by autoproteolysis to
produce the active form of the protein. This active form
is then secreted into the extracellular lysosome [30-32],
where it degrades bone matrix proteins, particularly type
I collagen, which constitutes 95% of the organic bone
matrix [3,5,15,20,33]. CTSK deficiency does not affect
the function of osteoclast-mediated extracellular acidifi-
cation [34]. Ctsk mutations were found to impair the
ability of osteoclasts to degrade collagen rather than
demineralize the extracellular matrix.
On the other hand, CTSK may also act as a potential
regulator of apoptosis and senescence, controlling osteo-
clast numbers in vivo [34]. Thus, impairment of CTSK-
mediated osteoclast apoptosis/senescence may also be
responsible for the higher number of osteoclasts found
in Ctsk
-/- mice [34].
In immunocytes
A pycnodysostosis patient with normal immune status
was reported in 1999 [35]. However, impaired killing
activity of monocytes with normal phagocytic capacity
and decreased levels of IL-1 secretion were reported in
pycnodysostosis patients in an earlier study [36].
In an early animal study, abnormities of histological
morphology or cellularity were found neither in the thy-
mus nor in the levels of B and T lymphocytes in periph-
eral blood [37]. Fluorescence-activated cell sorter analysis
showed no difference in the lymphocyte markers (CD4,
CD8, CD3, B220, IgM, and IgD) between Ctsk
-/- and
wild-type mice. Immunophenotype analysis of the cell
types in the bone marrow revealed a significant decrease
in the absolute cell number of all subtypes, even though
t h ep e r c e n t a g eo fe a c hs u b t y p ei nt h ee n t i r ep o p u l a t i o n
was unchanged [37].
Recently, Ctsk was found to function in the endo-
somes of dendritic cells. Pharmacological inhibition or
targeted disruption of Ctsk led to defective Toll-like
receptor 9 signaling in dendritic cells when stimulated
with cytosine-phosphate- guanine, but not when stimu-
lated with lipopolysaccharide or peptidoglycan. It was
shown that Ctsk is indispensable for differentiation of
dendritic cells, but not required for antigen uptake, pro-
cessing, or presentation by dendritic cells. The same
study also indicated that the ability of dendritic cells to
induce T helper 17 (Th17) cells was markedly inhibited
by Ctsk inactivation, which may be caused by a reduc-
tion in the expression of Th17 cell-related cytokines,
such as IL-6 and IL-23, by dendritic cells. Furthermore,
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-/- mice were resistant to experimental autoimmune
encephalomyelitis, in which Th17 cells are involved [26].
These results suggest that Ctsk plays an important role
in the immune system and may serve as a valid thera-
peutic target in autoimmune diseases.
Nevertheless, it remains to be determined whether
CTSK plays a pathogenic role in the human immune
system or in autoimmune/inflammatory diseases.
In other cells and tissues
New evidence suggests that CTSK is involved in extra-
cellular matrix remodeling in organs such as the lung,
thyroid, and skin, and plays a critical role in the devel-
opment and progression of cardiovascular disease [38].
Extensive destruction of elastin and collagen caused by
overexpression of cathepsins K and S has been related
to the damage and inflammation of arterial wall, result-
ing in atherogenesis [15,38-41].
Variants in the CTSK gene
Thirty three different mutations have been reported in 59
pycnodysostosis families [1,3,8,9,14,17,20,42-54] (Table 1,
Figure 1A). The Arg241 in exon 6 and Ala277 located in
CpG dinucleotides in exon 7 are two mutational hot
spots for pycnodysostosis (Figure 1B). Various mutations
have been reported in pycnodysostosis patients, including
23 missense mutations (69.70%), 4 frame-shift mutations
(12.12%), 3 nonsense mutations (9.09%), 2 splicing muta-
tions (6.06%), and 1 termination codon mutation (3.03%)
(Figure 1C). A total of 69.70% of the mutations occur in
t h em a t u r ed o m a i no fCTSK, 24.24% in the proregion,
and 6.06% in the preregion (Figure 1D).
The reported families and characteristics of different
mutations are summarized in Table 2. In addition to
paternal uniparental disomy in 1 family, compound het-
erozygous mutations were found in 14 afflicted families
(23.73%), while homozygous mutations were found in 44
afflicted families (74.58%). Of the 59 unrelated families,
37.29% were from Europe while 30.51% came from Asia.
Characteristics of mutant CTSK proteins
In order to determine CTSK expression, monocyte-
derived macrophages were isolated from the peripheral
blood of 2 siblings suffering from pycnodysostosis and
their unaffected parents. Western blot revealed no
detectable expression of either the proform or mature
form of CTSK in either affected sibling with p.Gly79Glu
and p.Lys52X. The levels of both proform and mature
forms of CTSK in the father, a carrier of p.Gly79Glu,
were nearly half that in normal controls, while the levels
in the mother, a carrier of p.Lys52X, were more severely
decreased [50]. In another study, monocytes were iso-
lated from the peripheral blood of a patient with p.
Ala141Val and induced to differentiate into osteoclasts
in vitro. As a result of the mutation, the ability of the
patient-derived cells to resorb bone was significantly
decreased [46].
Functional properties of CTSK mutants (p.Leu7Pro,
p.Leu9Pro, p.Gly79Glu, p.Gly146Arg, p.Gln165Arg, p.
Gly194Ser, p.Tyr212Cys, p.Ile249Thr, p.Asp250Gly, p.
Ala277Glu, p.Ala277Val, p.Arg312Gly, p.Gly319Cys,
and p.X330Trp) were examined by transient expression
in COS-7 cells, 293 cells, and Pichia pastoris GS115
cells, respectively [14,17,20,54]. Western blot analysis
revealed that the mutants affecting residues of the
mature domain yielded a mature form of a nonfunc-
tional protein, while the mutants p.Leu7Pro, p.Leu9-
Pro, and p.X330Trp yielded a trace amount of this
protein. In order to further understand the protein
consequences of these missense mutations, amino acid
changes of the mutant proteins, including p.Leu7Pro,
p.Leu9Pro, p.Gln165Arg, p.Gly194Ser, p.Ile249Thr, p.
Asp250Gly, and p.Gly319Cys, were modeled into the
three-dimensional structure of the full-length CTSK.
These mutations are predicted to affect the conforma-
tion of the protein [14].
All of these methods, including isolation of monocytes
from the pycnodysostosis patients and transfection in
COS-7 cells, 293 cells, and P. pastoris GS115 cells,
demonstrated that CTSK mutants are functionally dif-
ferent from the wild type.
Ctsk
-/- mouse models
The murine Ctsk gene maps to chromosome 3, and its
predicted amino acid sequence is highly homologous to
the human protein (85% identity; 93% similarity) [11].
Ctsk
-/- m o u s em o d e l sp l a yq u i t ea ni m p o r t a n tr o l ei n
studying the nature and function of Ctsk in osteoclasts
and other cells, in detecting the mechanisms of pheno-
types of pycnodysostosis, and even in optimizing thera-
peutic strategies (including gene therapy) for the
treatment of this genetic disorder [34,55]. A homozygous
null mutation in the mouse Ctsk gene was first estab-
lished in 1998. Ctsk
-/- mouse strains have been generated
in different genetic backgrounds since then [34,37,56-58].
All Ctsk
-/- mouse strains could mimic the phenotype of
human pycnodysostosis to different extents.
Generally, Ctsk deficient mice may survive and are fer-
tile. The phenotype of Ctsk
-/- mice resembles clinical char-
acteristics of the human pycnodysostosis in several
aspects, such as the presence of osteopetrosis, reduced
bone marrow cellularity, and splenomegaly after 2 months
of age [37,58]. Using radiography, micro-computed tomo-
graphy, and histological analyses, Ctsk
-/- mice were shown
to display an osteopetrotic phenotype with excessive trabe-
culation of the bone marrow space [56]. Deficiency of Ctsk
affects the late stage of the osteoclastic resorption cycle.
As a result, Ctsk
-/- mice are unique among the currently
available osteopetrotic mouse models [56].
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Location in DNA
sequence
Genomic DNA sequence
variants
Coding DNA sequence
variants
Effect on amino
acid
Location in protein
sequence
First description
Missense
Exon 2 g.1551T > C c.20T > C p.Leu7Pro Pre Donnarumma, et al.,
2007
Exon 2 g.1557T > C c.26T > C p.Leu9Pro Pre Nishi, et al., 1999
Exon 3 g.2128C > T c.136C > T p.Arg46Trp Pro Schilling, et al., 2007
Exon 3 g.2227G > A c.235G > A p.Gly79Arg Pro Fratzl-Zelman, et al.,
2004
Exon 3 g.2228G > A c.236G > A p.Gly79Glu Pro Hou, et al., 1999
Exon 5 g.4120C > T c.422C > T p.Ala141Val Mature Chavassieux, et al.,
2008
Exon 5 g.4134G > C c.436G > C p.Gly146Arg Mature Gelb, et al., 1996
Exon 5 g.4192A > G c.494A > G p.Gln165Arg Mature Donnarumma, et al.,
2007
Exon 5 g.4258A > C c.560A > C p.Gln187Pro Mature Li, et al., 2009
Exon 5 g.4278G > A c.580G > A p.Gly194Ser Mature Donnarumma, et al.,
2007
Exon 6 g.8644A > G c.635A > G p.Tyr212Cys Mature Hou, et al., 1999
Exon 6 g.8737 G > A c.728G > A p.Gly243Glu Mature Khan et al., 2010
Exon 6 g.8755T > C c.746T > C p.Ile249Thr Mature Donnarumma, et al.,
2007
Exon 6 g.8758A > G c.749A > G p.Asp250Gly Mature Donnarumma, et al.,
2007
Exon 7 g.9109C > T c.830C > T p.Ala277Val Mature Gelb, et al., 1998
Exon 7 g.9109C > A c.830C > A p.Ala277Glu Mature Hou, et al., 1999
Exon 7 g.9171T > C c.892T > C p.Trp298Arg Mature Nishi, et al., 1999
Exon 8 g.9186G > A c.908G > A p.Gly303Glu Mature Toral-Lopez et al.,
2010
Exon 8 g.11474T > C c.926T > C p.Leu309Pro Mature Haagerup, et al.,
2000
Exon 8 g.11479G > C c.931G > C p.Ala311Pro Mature Nishi, et al., 1999
Exon 8 g.11482C > G c.934C > G p.Arg312Gly Mature Hou, et al., 1999
Exon 8 g.11501G > A c.953G > A p.Cys318Tyr Mature Bertola et al., 2010
Exon 8 g.11503G > T c.955G > T p.Gly319Cys Mature Donnarumma, et al.,
2007
Nonsense
Exon 3 g.2146A > T c.154A > T p.Lys52X Pro Hou, et al., 1999
Exon 5 g.4266C > T c.568C > T p.Gln190X Mature Hou, et al., 1999
Exon 6 g.8730C > T c.721C > T p.Arg241X Mature Gelb, et al., 1996
Frameshifts (duplication)
Exon 2 g.1591-1592dupGA c.60_61dupGA p.Ile21ArgfsX29 Pro Donnarumma, et al.,
2007
Exon 4 g.2359dupA c.282dupA p.Val95SerfsX9 Pro Donnarumma, et al.,
2007
Frameshifts (deletion)
Exon 3 g.2230delG c.238delG p.Asp80ThrfsX2 Pro Fratzl-Zelman, et al.,
2004
Exon 5 g.4124delT c.426delT p.
Phe142LeufsX19
Mature Fujita, et al., 2000
Splicing
Intron2 g.2112G > A c.121-1G > A p.del41Val-81Met Pro Haagerup, et al.,
2000
Exon 7 g.9169G > A c.890G > A; 785_890del p.Gly262AlafsX70 Mature Donnarumma, et al.,
2007
Stop codon
Exon 8 g.11538A > G c.990A > G p.X330TrpextX19 Mature Gelb, et al., 1996
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-/- mice generally have minor craniofacial anoma-
lies, such as increased density of the maxilla and parana-
sal sinus bones as well as alterations in mandibular
shape [37]. Other skeletal changes seen in pycnodysosto-
sis patient, such as growth retardation, phalangeal defor-
mities, and delayed suture closure in the skull, have
seldom been reported in Ctsk
-/- mice. Recent studies
f o u n dt h a tt h ep y c n o d y s o s t o s i sp h e n o t y p ei nCtsk
-/-
mice is background-dependent. Compared with other
strains of Ctsk
-/- mice, the phenotypical characteristics
of 129/Sv Ctsk
-/- mice were similar to those of human
pycnodysostosis, including short stature, osteopetrosis in
Figure 1 Reported mutations of CTSK. (A) Distribution of the CTSK gene and polypeptide mutations. The genomic structure of the CTSK gene
with 8 exons (purple boxes numbered 1-8) is shown in the top half. The bottom half illustrates the schematic representation of the polypeptide
comprising a 15-amino acid preregion (yellow box), a 99-residue proregion (light blue boxes), and a 215-amino acid mature domain (orange
boxes). A total of 23 missense mutations (black type) are represented at the top of the gene diagram, while frame-shift mutations (red type),
nonsense mutations (light green type), splicing mutations (blue type), and termination codon mutations (yellow type) are at the bottom. (B)
Frequency of different mutations. The height of each bar represents the number of afflicted families. #: Both mutations in the Glu70 residue. ##:
Both mutations in the Ala277 residue. (C) The type of reported CTSK mutations. The mutations reported in pycnodysostosis patients consist of 23
missense mutations, 4 frame-shift mutations, 3 nonsense mutations, 2 splicing mutations, and 1 termination codon mutation. (D) Distribution of
reported CTSK mutations. A total of 69.70% of the mutations occurred in the mature domain, 24.24% in the proregion, and 6.06% in the
preregion.
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Allele 1 Allele 2 Patients
reported
Unrelated
families
Nationality of
patients
Reference
c.436G > C c.436G > C 1 1 Algerian Osimani, et al., 2009
c.436G > C c.721C > T 1 1 American Hispanic Gelb, et al., 1996
c.235G > A c.238delG 1 1 Austria Fratzl-Zelman, et al., 2004
c.934C > G c.934C > G 1 1 Austria Fratzl-Zelman, et al., 2004
c.830C > T c.830C > T 1 1 Belgian Gelb, et al., 1998
c.953G > A c.953G > A 2 2 Brazil Bertola et al., 2010
c.953G > A c.721C > T 1 1 Brazil Bertola et al., 2010
c.721C > T c.436G > C 1 1 Brazil Bertola et al., 2010
c.721C > T c.721C > T 2 2 Brazil Bertola et al., 2010
c.494A > G c.721C > T 1 1 Caucasian Laffranchi et al., 2010
c.154A > T c.236G > A 2 1 Caucasian Ho, et al., 1999
c.560A > C c.560A > C 1 1 Chinese Li, et al., 2009
c.121-1G > A c.926T > C 1 1 Denmark Haagerup, et al., 2000
c.236G > A c.926T > C 1 1 Denmark Haagerup, et al., 2000
c.926T > C c.926T > C 6 3 Denmark Haagerup, et al., 2000
c.890G > A;
785_890del
c.890G > A;
785_890del
1 1 Egypt Donnarumma, et al., 2007
c.136C > T c.136C > T 3 1 Germany Schilling, et al., 2007
c.934C > G c.934C > G 2 1 Honduran Hou, et al., 1999
c.830C > A c.830C > A 1 1 Indian Hou, et al., 1999
c.990A > G c.990A > G 16 1 Israeli Arab Gelb, et al., 1996
c.20T > C c.580G > A 1 1 Italy Donnarumma, et al., 2007
c.494A > G c.721C > T 1 1 Italy Donnarumma, et al., 2007
c.26T > C c.26T > C 2 2 Japanese Nishi, et al., 1999; Fujita, et al., 2000
c.26T > C c.892T > C 1 1 Japanese Nishi, et al., 1999
c.426delT c.426delT 2 2 Japanese Fujita, et al., 2000
c.830C > T c.830C > T 3 3 Japanese Nishi, et al., 1999; Fujita, et al., 2000
c.721C > T c.721C > T 10 1 Mexican Johnson, et al., 1996
c.908G > A c.908G > A 3 1 Mexican Toral-Lopez et al., 2010
c.60_61dupGA c.60_61dupGA 3 1 Moroccan Donnarumma, et al., 2007
c.436G > C c.436G > C 1 1 Moroccan Rothenbuhler et al., 2010
c.436G > C c.436G > C 2 1 Moroccan Arab Gelb, et al., 1996
c.282dupA c.282dupA 1 1 Pakistan Donnarumma, et al., 2007
c.728G > A c.728G > A 5 1 Pakistani Khan et al., 2010
c.749A > G c.749A > G 1 1 Pakistan Donnarumma, et al., 2007
c.830C > T c.830C > T 5 3 Pakistan Donnarumma, et al., 2007; Naeem, et al.,
2009
c.955G > T c.955G > T 1 1 Pakistan Donnarumma, et al., 2007
c.721C > T c.721C > T 2 2 Portuguese Hou, et al., 1999; Donnarumma, et al.,
2007
c.830C > A c.830C > A 1 1 Portuguese Hou, et al., 1999
c.635A > G c.721C > T 1 1 Spanish Hou, et al., 1999
c.721C > T c.746T > C 1 1 Spanish Donnarumma, et al., 2007
c.721C > T c.721C > T 1 1 Spanish Rothenbuhler et al., 2010
c.931G > C c.931G > C 2 1 Swiss Nishi, et al., 1999
c.436G > C c.436G > C 1 1 Tunisia Donnarumma, et al., 2007
c.154A > T c.236G > A 1 1 * Hou, et al., 1999
c.568C > T c.568C > T 1 1 * Hou, et al., 1999
c.830C > T c.830C > T 1 1 * Hou, et al., 1999
c.422C > T c.422C > T 1 1 Unknown Chavassieux, et al., 2008
c.721C > T c.721C > T 3 1 Unknown Everts, et al., 2003
*: Two of the three families are from northern Europe, while the other is from Czech (no detailed record can be found in corresponding papers).
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lity, separated cranial sutures with open fontanels, loss
of the mandibular angle, lack of normal occlusion, and
enhanced open bite [34].
A transgenic mouse model overexpressing the Ctsk
gene showed that excess Ctsk production resulted in a
high turnover of the metaphyseal trabecular bone.
Enhanced bone resorption in these mice led to increased
osteoblast numbers and activities, possibly mediated by
core-binding protein a1, a transcription factor essential
for osteoblast differentiation [56].
Clinical relevance
A series of typical features in clinical and radiological
examinations have been observed in pycnodysostosis.
We summarized the manifestations in 97 reported cases
(Table 3) [1-10,17,35,42-47,50,52,53,59-91]. The most
common phenotype of pycnodysostosis is short stature,
which was reported in 95.9% of the 97 reported cases.
The next most common phenotype is an increase in
bone density, which was reported in 88.7% of the 97
patients. Open fontanels and sutures with frontal and
parietal bossing, frequent fractures, hypoplasia of the
maxilla and mandible with an obtuse mandibular angle,
and stubby hands and feet with acroosteolysis of the dis-
tal phalanges were identified in more than 50% of the
pycnodysostosis patients. Approximately one-third of
the pycnodysostosis patients showed prominent eyes
with bluish sclera. Additionally, these patients also show
some dental defects, such as delayed eruption of perma-
nent teeth with persistence of deciduous teeth, dental
crowding, and malocclusion, which may be ignored by
clinicians.
In addition to the typical manifestations mentioned
above, some unusual findings, including hearing loss [5],
central giant-cell granuloma of the maxilla [82], conge-
nital pseudarthrosis of the clavicle [7], spondylolysis
[79], and bone marrow hypoplasia with compensatory
splenomegaly [76], were reported in pycnodysostosis
patients.
Pycnodysostosis patients usually have normal life
expectancies and mentations. Results of laboratory
investigations, including leukocyte and thrombocyte
number; mean corpuscular volume (MCV); and the
levels of hemoglobin (Hb), plasma phosphate, calcium,
and alkaline phosphatase, are usually within normal lim-
its [1,3-5].
Physiopathological mechanism of pycnodysostosis
Abnormal bone metabolism is the typical physiopatholo-
gical characterics of pycnodysostosis. The most common
phenotype of pycnodysostosis is short stature. Based on
the results of animal experiments, the short stature in
pycnodysostosis may be related to the reduced size of
the long bones [37].
In addition, pycnodysostosis patients usually suffer
from pathologic fractures as a result of brittle, chalk-like
bones. Histomorphometric and biomechanical assays in
Ctsk
-/- mice have suggested that CTSK may play a criti-
cal role in matrix formation as well as breakdown. Large
amounts of brittle, poorly organized matrix were formed
in the absence of Ctsk gene, which corresponds to the
bone fragility observed in patients with CTSK deficiency
[57].
The coexistence of increased bone density in long
bones (osteosclerosis) and osteolysis in the distal pha-
langes and calvariae is a typical characteristic of pycno-
dysostosis with CTSK mutation. One explanation may
be the site-specific variations in bone homeostasis. It
was reported that CTSK is clearly important to bone
Table 3 Typical clinical features of pycnodysostosis*
Typical features Positive Negative Not mentioned
Short stature (<150 cm) 93(95.9%) 0 4(4.1%)
Increase of bone density 86(88.7%) 0 11(11.3%)
Open fontanels and sutures 68-73(70.1%-75.3%) 0 24-29(24.7%-29.9%)
Frontal and parietal bossing 67-72(69.1%-74.2%) 0 25-30(25.8%-30.9%)
Fractures 65(67.0%) 3(3.1%) 29(29.9%)
Obtuse mandibular angle 63(64.9%) 0 34(35.1%)
Hypoplasia of the jaws 53-61(54.6%-62.9%) 0 36-44(37.1%-45.4%)
Stubby hands and feet with osteolysis of the distal phalanges 43-50(44.3%-51.5%) 0 47-54(48.5%-55.7%)
Prominent eyes with bluish sclerae 34(35.1%) 0 63(64.9%)
Grooved palate 20-28(20.6%-28.9%) 0 69-77(71.1%-79.4%)
Dysplastic nails 26(26.8%) 0 71(73.2%)
Clavicular dysplasia 24(24.7%) 0 73(75.3%)
Nonpneumatised paranasal sinuses 17(17.5%) 0 80(82.5%)
Beaked nose 16(16.5%) 0 81(83.5%)
*n = 97 (44 females, 42 males, and 11 unknown)
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bones), while it is not the most essential factor in regu-
lating the bone resorption in bones with low turnover
rates, such as the calvaria and epiphysis [34,37,48]. On
the other hand, animal experiments have shown that
metalloproteinases participate in osteoclastic resorption
of calvarial bones, but not of long bones [34]. The
increased number of Ctsk
-/- osteoclasts may result in
excessive bone resorption in the distal end of long
bones (osteolysis), and the impaired ability of osteoclasts
may account for the osteopetrosis in the main body of
long bones [34,37,48,56].
Immunophenotype analysis of the cell types in the
bone marrow of Ctsk
-/- mice revealed reductions in
absolute cell numbers, but not in the percentages of all
the different subtypes, indicating that marrow hypoplasia
results from the reduction in bone marrow cavity space,
which is caused by osteopetrosis. As a result, extrame-
dullary hematopoiesis occurs in the spleen (enlarged
with a significantly elevated cellularity) to compensate
for the reduced bone marrow cellularity [37].
Diagnosis and differential diagnoses
Although CTSK gene mutation analysis is the confirma-
tory test for pycnodysostosis, the diagnosis can be estab-
lished primarily based on the aforementioned clinical
features and radiograph findings [5]. On the other hand,
pycnodysostosis should be distinguished from other
g e n e t i cb o n ed i s e a s e s ,p a r t i c u l arly cleidocranial dysosto-
sis (CCD) and osteopetrosis [5,47,68]. Clavicular hypo-
plasia and typical craniofacial characteristics, especially
the open fontanels and cranial sutures in pycnodysosto-
sis, may lead to misdiagnosis of cleidocranial dysplasia.
However, increased bone density with recurrent fractures
is highly suggestive of pycnodysostosis [92-95]. Short sta-
ture and generalized osteosclerosis with multiple frac-
tures in pycnodysostosis patients has been misdiagnosed
as osteopetrosis [71,96-98]. However, acroosteolysis of
the distal phalanges and unclosed cranial sutures and
fontanels are indicative of pycnodysostosis.
Treatment
To date, no specific treatment has been validated in pyc-
nodysostosis with the exception of symptomatic man-
agement [5,46]. Because bone fractures are a primary
threat to these patients, it is important to prevent frac-
ture-causing factors. These patients are likely to visit
dentists because oral deformities severely affect their
life. Here, we would like to emphasize the role of den-
tists in the diagnosis and treatment of this condition.
Maintenance of oral hygiene and regular dental care
may help prevent some oral complications. However,
the greater bone density increases the probability of
developing postextraction osteomyelitis. Thus, risk fac-
tors should be carefully addressed while planning tooth
extraction and other treatments. In summary, it is quite
important to establish a correct diagnosis as early as
possible to prevent fractures and ensure a better quality
of life [5,6,54].
Future prospects
Genotype-phenotype correlation draws great attention in
the field of genetic disorder research. Clinical features with
CTSK genetic analysis were reported in 42 pycnodysosto-
sis patients from 24 families [1,3,8,9,17,42-47,50,52,53].
However, the detailed clinical information was poorly
described in most of the reports with molecular data. Lack
of good clinical information makes it difficult to evaluate
of the genotype-phenotype correlation of pycnodysostosis.
More detailed information about the clinical and genetic
characteristics in pycnodysostosis patients are necessary
for the further research to elucidate the CTSK genotype-
phenotype correlation.
Research on specific approaches to correct the abnor-
mal bone metabolism in pycnodysostosis is another hot
topic. Due to providing normal osteoclasts and osteo-
clast-targeted enzymes, bone marrow transplantation is
drawing the increasing attention. Gene replacement
strategies are other alternative choices. However, consid-
erable research is required in this area [54].
Recently, CTSK was shown to play an important role in
autoimmune and inflammatory diseases by animal and in
vitro experiments [26]. If the role of CTSK in the human
immune system is confirmed [99], it will be helpful in
further understanding of the mechanism of pycnodysos-
tosis and in designing specific treatment strategies.
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